Matthew A Downey1, Maxwell J Giammona1, Christian A Lang2, Steven K Buratto1, Ambuj Singh2,3, Michael T Bowers4. 1. Department of Chemistry and Biochemistry, University of California, Santa Barbara, CA, 93106, USA. 2. Acelot, Inc., 5385 Hollister Ave, Suite 111, Santa Barbara, CA, 93111, USA. 3. Department of Computer Science, University of California, Santa Barbara, CA, 93106, USA. 4. Department of Chemistry and Biochemistry, University of California, Santa Barbara, CA, 93106, USA. bowers@chem.ucsb.edu.
Abstract
Alzheimer's disease (AD) is rapidly reaching epidemic status among a burgeoning aging population. Much evidence suggests the toxicity of this amyloid disease is most influenced by the formation of soluble oligomeric forms of amyloid β-protein, particularly the 42-residue alloform (Aβ42). Developing potential therapeutics in a directed, streamlined approach to treating this disease is necessary. Here we utilize the joint pharmacophore space (JPS) model to design a new molecule [AC0107] incorporating structural characteristics of known Aβ inhibitors, blood-brain barrier permeability, and limited toxicity. To test the molecule's efficacy experimentally, we employed ion mobility mass spectrometry (IM-MS) to discover [AC0107] inhibits the formation of the toxic Aβ42 dodecamer at both high (1:10) and equimolar concentrations of inhibitor. Atomic force microscopy (AFM) experiments reveal that [AC0107] prevents further aggregation of Aβ42, destabilizes preformed fibrils, and reverses Aβ42 aggregation. This trend continues for long-term interaction times of 2 days until only small aggregates remain with virtually no fibrils or higher order oligomers surviving. Pairing JPS with IM-MS and AFM presents a powerful and effective first step for AD drug development. Graphical Abstract.
Alzheimer's disease (n class="Disease">AD) is rapidly reaching epidemic status among a burgeoning aging population. Much evidence suggests the toxicity of this amyloid disease is most influenced by the formation of soluble oligomeric forms of amyloid β-protein, particularly the 42-residue alloform (Aβ42). Developing potential therapeutics in a directed, streamlined approach to treating this disease is necessary. Here we utilize the joint pharmacophore space (JPS) model to design a new molecule [AC0107] incorporating structural characteristics of known Aβ inhibitors, blood-brain barrier permeability, and limited toxicity. To test the molecule's efficacy experimentally, we employed ion mobility mass spectrometry (IM-MS) to discover [AC0107] inhibits the formation of the toxic Aβ42 dodecamer at both high (1:10) and equimolar concentrations of inhibitor. Atomic force microscopy (AFM) experiments reveal that [AC0107] prevents further aggregation of Aβ42, destabilizes preformed fibrils, and reverses Aβ42 aggregation. This trend continues for long-term interaction times of 2 days until only small aggregates remain with virtually no fibrils or higher order oligomers surviving. Pairing JPS with IM-MS and AFM presents a powerful and effective first step for AD drug development. Graphical Abstract.
Entities:
Keywords:
Aggregation; Alzheimer’s disease; Amyloid-β protein; Atomic force microscopy; Aβ42; Inhibition; Ion mobility mass spectrometry; Joint pharmacophore space
Authors: Harry LeVine; Qunxing Ding; John A Walker; Randal S Voss; Corinne E Augelli-Szafran Journal: Neurosci Lett Date: 2009-08-05 Impact factor: 3.046
Authors: Timothy M Ryan; Blaine R Roberts; Gawain McColl; Dominic J Hare; Philip A Doble; Qiao-Xin Li; Monica Lind; Anne M Roberts; Haydyn D T Mertens; Nigel Kirby; Chi L L Pham; Mark G Hinds; Paul A Adlard; Kevin J Barnham; Cyril C Curtain; Colin L Masters Journal: J Neurosci Date: 2015-02-18 Impact factor: 6.167
Authors: Gwendolyn T Wong; Denise Manfra; Frederique M Poulet; Qi Zhang; Hubert Josien; Thomas Bara; Laura Engstrom; Maria Pinzon-Ortiz; Jay S Fine; Hu-Jung J Lee; Lili Zhang; Guy A Higgins; Eric M Parker Journal: J Biol Chem Date: 2004-01-06 Impact factor: 5.157